1
|
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events.
|
Nat Biotechnol
|
2008
|
4.46
|
2
|
Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate.
|
Curr Pharm Des
|
2007
|
2.14
|
3
|
Generation of "neoheparin" from E. coli K5 capsular polysaccharide.
|
J Med Chem
|
2005
|
2.03
|
4
|
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
|
Blood
|
2007
|
1.49
|
5
|
SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.
|
Clin Cancer Res
|
2011
|
1.40
|
6
|
Orthogonal analytical approaches to detect potential contaminants in heparin.
|
Proc Natl Acad Sci U S A
|
2009
|
1.36
|
7
|
Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models.
|
FASEB J
|
2005
|
1.32
|
8
|
The impact of heparanese and heparin on cancer metastasis and angiogenesis.
|
Pathophysiol Haemost Thromb
|
2006
|
1.29
|
9
|
Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer.
|
Matrix Biol
|
2010
|
1.21
|
10
|
P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins.
|
FASEB J
|
2007
|
1.14
|
11
|
Complex glycosaminoglycans: profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy.
|
Anal Biochem
|
2005
|
1.09
|
12
|
Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy.
|
Semin Thromb Hemost
|
2007
|
1.08
|
13
|
Structural features of low-molecular-weight heparins affecting their affinity to antithrombin.
|
Thromb Haemost
|
2009
|
1.06
|
14
|
Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo.
|
Blood
|
2014
|
1.03
|
15
|
Undersulfated and glycol-split heparins endowed with antiangiogenic activity.
|
J Med Chem
|
2004
|
0.99
|
16
|
Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors.
|
Biochemistry
|
2002
|
0.96
|
17
|
Heparanase, heparin and the coagulation system in cancer progression.
|
Thromb Res
|
2007
|
0.95
|
18
|
The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
|
Thromb Res
|
2011
|
0.89
|
19
|
Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist.
|
Glycobiology
|
2004
|
0.87
|
20
|
Chemical derivatization as a strategy to study structure-activity relationships of glycosaminoglycans.
|
Semin Thromb Hemost
|
2002
|
0.86
|
21
|
Profiling glycol-split heparins by high-performance liquid chromatography/mass spectrometry analysis of their heparinase-generated oligosaccharides.
|
Anal Biochem
|
2012
|
0.85
|
22
|
Minimal heparin/heparan sulfate sequences for binding to fibroblast growth factor-1.
|
Biochem Biophys Res Commun
|
2002
|
0.84
|
23
|
Active conformations of glycosaminoglycans. NMR determination of the conformation of heparin sequences complexed with antithrombin and fibroblast growth factors in solution.
|
Semin Thromb Hemost
|
2002
|
0.82
|
24
|
Characterizing the microstructure of heparin and heparan sulfate using N-sulfoglucosamine 1H and 15N NMR chemical shift analysis.
|
Anal Chem
|
2012
|
0.82
|
25
|
The tainted heparin story: an update.
|
Thromb Haemost
|
2009
|
0.82
|
26
|
High-performance liquid chromatographic/mass spectrometric studies on the susceptibility of heparin species to cleavage by heparanase.
|
Semin Thromb Hemost
|
2007
|
0.80
|
27
|
Insights into the human glycan receptor conformation of 1918 pandemic hemagglutinin-glycan complexes derived from nuclear magnetic resonance and molecular dynamics studies.
|
Biochemistry
|
2014
|
0.79
|
28
|
Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: role in osteoclastogenesis and bone resorption.
|
Eur J Cell Biol
|
2010
|
0.79
|
29
|
Interactions of low-molecular-weight semi-synthetic sulfated heparins with human leukocyte elastase and human Cathepsin G.
|
Biochem Pharmacol
|
2005
|
0.79
|
30
|
Structural features of glycol-split low-molecular-weight heparins and their heparin lyase generated fragments.
|
Anal Bioanal Chem
|
2013
|
0.78
|
31
|
O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis.
|
Semin Thromb Hemost
|
2007
|
0.78
|
32
|
Reversed-phase ion-pair ultra-high-performance-liquid chromatography-mass spectrometry for fingerprinting low-molecular-weight heparins.
|
J Chromatogr A
|
2013
|
0.77
|
33
|
Modulation of antithrombin-protease interactions by semisynthetic low-molecular-weight heparins with different sulfation patterns.
|
Semin Thromb Hemost
|
2003
|
0.76
|
34
|
Inhibitory effects of glycosaminoglycans on basal and stimulated transforming growth factor-β1 expression in mesangial cells: biochemical and structural considerations.
|
Glycobiology
|
2011
|
0.75
|
35
|
Electrochemical characterisation of 6-iodomaltose, 6'-iodomaltose and 6-iodomaltotriose on a silver cathode and their one-pot electrochemical dimerisation to new mixed O/C maltotetraose and maltohexaose mimics.
|
Chemistry
|
2009
|
0.75
|
36
|
Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide.
|
Semin Thromb Hemost
|
2002
|
0.75
|
37
|
Effects of calcium ions on the interactions between antithrombin and factor Xa mediated by variously sulfated, semisynthetic low-molecular-weight heparins.
|
Semin Thromb Hemost
|
2002
|
0.75
|
38
|
Low-molecular-weight heparin and dermatan sulfate end group-labeled with tyramine and fluorescein. Biochemical and biological characterization of the fluorescent-labeled heparin derivative.
|
Semin Thromb Hemost
|
2002
|
0.75
|
39
|
Structure of a heteroxylan of gum exudate of the palm Scheelea phalerata (uricuri).
|
Phytochemistry
|
2004
|
0.75
|